192 related articles for article (PubMed ID: 32654325)
1. Vascular endothelial growth factor-A as a promising therapeutic target for the management of psoriasis.
Luengas-Martinez A; Hardman-Smart J; Paus R; Young HS
Exp Dermatol; 2020 Aug; 29(8):687-698. PubMed ID: 32654325
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor (VEGF) in the pathogenesis of psoriasis--a possible target for novel therapies?
Canavese M; Altruda F; Ruzicka T; Schauber J
J Dermatol Sci; 2010 Jun; 58(3):171-6. PubMed ID: 20430590
[TBL] [Abstract][Full Text] [Related]
3. Targeting VEGF/VEGFR in the treatment of psoriasis.
Li W; Man XY; Chen JQ; Zhou J; Cai SQ; Zheng M
Discov Med; 2014 Sep; 18(98):97-104. PubMed ID: 25227750
[TBL] [Abstract][Full Text] [Related]
4. Complete remission of psoriasis following bevacizumab therapy for colon cancer.
Akman A; Yilmaz E; Mutlu H; Ozdogan M
Clin Exp Dermatol; 2009 Jul; 34(5):e202-4. PubMed ID: 19077094
[TBL] [Abstract][Full Text] [Related]
5. Excessive angiogenesis associated with psoriasis as a cause for cardiovascular ischaemia.
Malecic N; Young HS
Exp Dermatol; 2017 Apr; 26(4):299-304. PubMed ID: 28156019
[TBL] [Abstract][Full Text] [Related]
6. Investigational VEGF antagonists for psoriasis.
Crawshaw AA; Griffiths CE; Young HS
Expert Opin Investig Drugs; 2012 Jan; 21(1):33-43. PubMed ID: 22088218
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide Improves Psoriasis-like Lesions and Inhibits Cutaneous VEGF Expression without Alteration of Microvessel Density in Imiquimod- induced Psoriatic Mouse Model.
Liu JH; Wu HH; Zhao YK; Wang F; Gao Q; Luo DQ
Curr Vasc Pharmacol; 2018; 16(5):510-521. PubMed ID: 28982338
[TBL] [Abstract][Full Text] [Related]
8. Vascular Endothelial Growth Factor Blockade Induces Dermal Endothelial Cell Apoptosis in a Clinically Relevant Skin Organ Culture Model.
Luengas-Martinez A; Hardman-Smart J; Rutkowski D; Purba TS; Paus R; Young HS
Skin Pharmacol Physiol; 2020; 33(3):110-118. PubMed ID: 32570235
[TBL] [Abstract][Full Text] [Related]
9. Novel investigational vascular endothelial growth factor (VEGF) receptor antagonists for psoriasis.
Malecic N; Young HS
Expert Opin Investig Drugs; 2016; 25(4):455-62. PubMed ID: 26864055
[TBL] [Abstract][Full Text] [Related]
10. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies.
Frumovitz M; Sood AK
Gynecol Oncol; 2007 Mar; 104(3):768-78. PubMed ID: 17306693
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor and bevacitumab in breast cancer.
Bando H
Breast Cancer; 2007; 14(2):163-73. PubMed ID: 17485901
[TBL] [Abstract][Full Text] [Related]
13. Antivascular endothelial growth factor-A therapy: a novel personalized treatment approach for psoriasis.
Luengas-Martinez A; Paus R; Young HS
Br J Dermatol; 2022 May; 186(5):782-791. PubMed ID: 34878645
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy.
Shinkaruk S; Bayle M; Laïn G; Déléris G
Curr Med Chem Anticancer Agents; 2003 Mar; 3(2):95-117. PubMed ID: 12678905
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
Hsu JY; Wakelee HA
BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis--a new target for future therapy.
Pandya NM; Dhalla NS; Santani DD
Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
[TBL] [Abstract][Full Text] [Related]
17. Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway.
Itatani Y; Kawada K; Yamamoto T; Sakai Y
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670046
[TBL] [Abstract][Full Text] [Related]
18. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
19. A novel model of persistent retinal neovascularization for the development of sustained anti-VEGF therapies.
Li Y; Busoy JM; Zaman BAA; Tan QSW; Tan GSW; Barathi VA; Cheung N; Wei JJ; Hunziker W; Hong W; Wong TY; Cheung CMG
Exp Eye Res; 2018 Sep; 174():98-106. PubMed ID: 29852133
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.
Al Wadi K; Ghatage P
Expert Opin Pharmacother; 2016; 17(6):853-60. PubMed ID: 26933765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
